Indegene Limited , a leading digital-first, life sciences commercialization company, has reported a robust performance for the second quarter of fiscal year 2026, with significant revenue growth and strategic acquisitions to bolster its market position.

Financial Highlights

Indegene posted impressive financial results for Q2 FY26:

The company's revenue growth in USD terms stood at 12.4% year-on-year and 3.6% sequentially. The EBITDA margin, adjusted for one-time non-recurring M&A costs, experienced a 2% sequential decline, primarily due to annual wage hikes effective July 2025.

Segment Performance

The Enterprise segment, comprising Enterprise Commercial and Enterprise Medical Solutions, which contributes 88.5% of Indegene's revenue, grew by 8.1% quarter-on-quarter. However, this growth was partially offset by a 15.8% degrowth in the Brand Activation segment.

Strategic Acquisitions

Indegene announced two strategic acquisitions in October 2025:

1. BioPharm: A U.S.-based omnichannel marketing company, acquired for approximately $65.00 million.
2. WARN & CO: A U.K.-based boutique consulting firm, acquired for GBP 2.00 million plus future performance-linked payouts.

These acquisitions are expected to enhance Indegene's capabilities in omnichannel campaign execution and consulting services.

Business Highlights

• Secured two large deals exceeding $3.00 million Annual Contract Value (ACV) in the Enterprise Commercial Solutions segment.
• Won four deals in the $1-3 million ACV range across Enterprise Commercial and Enterprise Medical segments.
• Increased active customer base to 76 from 70 in the previous quarter.
• Tectonic offering generated approximately $2.00 million in revenue from four customers in H1 FY26.

Market Outlook and Strategy

Manish Gupta, Chairman and CEO of Indegene, commented on the evolving market dynamics: "We continue to see clients actively building on earlier digital and centralization themes. This is driven by top-down pressures the industry faces and the potential of AI to improve efficiency and effectiveness."

The company anticipates a temporary EBITDA margin compression of about 1.5% in the near term due to strategic investments, with expectations of recovery over 6-8 quarters.

Conclusion

Indegene's strong Q2 performance, coupled with strategic acquisitions and a growing deal pipeline, positions the company well for future growth. The focus on AI-driven initiatives and expanding capabilities in omnichannel marketing and consulting services aligns with the evolving needs of the life sciences industry.

As the pharmaceutical sector navigates challenges such as pricing pressures and regulatory changes, Indegene's digital-first approach and expanding service offerings may provide valuable solutions for clients seeking to enhance efficiency and effectiveness in their operations.

Indegene Limited , a tech-native life sciences specialist, has announced robust financial results for the second quarter of fiscal year 2026, demonstrating continued growth and strategic expansion.

Financial Highlights

Indegene reported a significant year-over-year revenue growth of 17.1%, with revenue from operations reaching INR 8,042.00 million for Q2 FY26. This marks the fourth consecutive quarter of strong growth for the company. In USD terms, the revenue growth stood at 12.4% year-over-year.

The company maintained a healthy profitability profile with an adjusted EBITDA of INR 1,461.00 million, representing an 18.2% margin. Profit after tax (PAT) for the quarter was INR 1,021.00 million, with a PAT margin of 12.7%.

Segment Performance

Indegene's core segments, Enterprise Commercial Solutions (ECS) and Enterprise Medical Solutions (EMS), showed strong performance:

• ECS revenue grew to INR 4,874.00 million, up 26.2% year-over-year
• EMS revenue increased to INR 2,242.00 million, up 13.4% year-over-year

The Brand Activation segment (formerly Omnichannel Activation) experienced a decline of 15.8% quarter-over-quarter, reflecting shifts in market dynamics.

Strategic Acquisitions

Indegene announced two strategic acquisitions to enhance its capabilities:

1. BioPharm: A US-based specialized marketing services agency, acquired for USD 104.00 million. This acquisition aims to strengthen Indegene's commercialization portfolio with AdTech capabilities.

2. WARN & Co.: A UK-based transformation consulting firm, acquired to enhance Indegene's expertise in business transformation consulting.

Operational Highlights

• Active client relationships increased to 76, up from 70 in the previous quarter
• The company maintained 40 clients with over $1 million in revenue
• Total employee count reached 5,245, with 4,523 in delivery roles

Management Commentary

Manish Gupta, Chairman and CEO of Indegene, stated, "We delivered strong growth for the fourth consecutive quarter, driven by continued momentum in deal wins and execution. A robust pipeline generation points to a positive industry outlook."

Suhas Prabhu, CFO, added, "In Q2FY26, our focus was on executing our strategic priorities: from business development to delivery, especially on newer engagement models like Tectonic; from technology enablement to bring AI to clients faster; to M&A to deepen our expertise and credibility."

Future Outlook

Indegene's management expressed confidence in the company's growth trajectory, citing a robust pipeline and positive industry outlook. The focus for the upcoming quarter will be on renewals and new wins to build a solid foundation for the next calendar year.

The strategic acquisitions of BioPharm and WARN & Co. are expected to bring advanced capabilities that align with Indegene's vision and future direction, potentially opening new avenues for growth and market expansion.

With its continued focus on innovation, strategic expansion, and client-centric approach, Indegene appears well-positioned to capitalize on the evolving needs of the life sciences industry.

Key Financial Metrics (Q2 FY26)

Investors and stakeholders will likely watch closely how Indegene leverages its recent acquisitions and strategic initiatives to drive further growth in the coming quarters.